0001562180-20-005393.txt : 20200811 0001562180-20-005393.hdr.sgml : 20200811 20200811165223 ACCESSION NUMBER: 0001562180-20-005393 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200807 FILED AS OF DATE: 20200811 DATE AS OF CHANGE: 20200811 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DEKKERS MARIJN E CENTRAL INDEX KEY: 0001216068 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38319 FILM NUMBER: 201093100 MAIL ADDRESS: STREET 1: GENERAL ELECTRIC COMPANY STREET 2: 41 FARNSWORTH STREET CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Quanterix Corp CENTRAL INDEX KEY: 0001503274 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 208957988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 MIDDLESEX TURNPIKE CITY: BILLERICA STATE: MA ZIP: 01821 BUSINESS PHONE: 617-301-9400 MAIL ADDRESS: STREET 1: 900 MIDDLESEX TURNPIKE CITY: BILLERICA STATE: MA ZIP: 01821 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-08-07 false 0001503274 Quanterix Corp QTRX 0001216068 DEKKERS MARIJN E C/O QUANTERIX CORPORATION, 900 MIDDLESEX TURNPIKE BILLERICA MA 01821 true false false false Common Stock 2020-08-07 4 S false 27619.00 32.49 D 0.00 I Held by Novalis LifeSciences Investments I, L.P. Common Stock 6810.00 D Reflects the portion of 117,378 shares of the Issuer's common stock held by Novalis LifeSciences Investments I, L.P. (the "Fund") in which the Reporting Person had a pecuniary interest. This transaction was executed in multiple trades at prices ranging from $32.3489 to $32.5662. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The Reporting Person had sole voting and investment control over all of the shares owned by the Fund and had a pecuniary interest in 27,619 of the shares. Includes 2,270 restricted stock units. /s/ Brian Keane, as Attorney-in-Fact 2020-08-11